Publication:
Assessment Of Antiviral Usage, Barriers, And Strategies For Scaling Up Hepatitis C Treatment In Malaysia: A Mix Methodology Study

Simple item page
dc.contributor.authorChan Huan Keat
dc.date.accessioned2024-05-02T09:45:20Z
dc.date.available2024-05-02T09:45:20Z
dc.date.issued2023-06
dc.description.abstractMalaysia adopted three key strategies to pursue the global goal of hepatitis C elimination, namely applying compulsory licensing on a direct-acting antiviral (DAA), introducing a standard DAA-based treatment regimen (sofosbuvir and daclatasvir) and decentralizing hepatitis C care through primary healthcare centers. This three-phase study adopted both quantitative and qualitative methods, aiming to (i) assess changes in the treatment coverage of individuals with hepatitis C and the government spending on antivirals after applying compulsory licensing, (ii) evaluate clinical outcomes in treatment recipients of the standard regimen, and (iii) explore barriers and potential strategies to further scale up pharmacological treatment under the existing hepatitis C care decentralization model.
dc.identifier.urihttps://erepo.usm.my/handle/123456789/19088
dc.subjectAssessment Of Antiviral Usage
dc.subjectBarriers
dc.subjectAnd Strategies
dc.subjectScaling Up Hepatitis C Treatment
dc.subjectMix Methodology Study
dc.subjectMalaysia
dc.titleAssessment Of Antiviral Usage, Barriers, And Strategies For Scaling Up Hepatitis C Treatment In Malaysia: A Mix Methodology Study
dc.typeResource Types::text::thesis::doctoral thesis
dspace.entity.typePublication
oairecerif.author.affiliationUniversiti Sains Malaysia
Files
Collections
Pusat Pengajian Sains Farmasi - Tesis